SCHEMBL30714644

SCHEMBL30714644

Cn1nc2ccc(OCc3ccccn3)cc2c1C(=O)NC1(CO)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMO Q99835 5/20 0.40
MAPK14 Q16539 4/20 0.40
PARP10 Q53GL7 1/20 0.38
MET P08581 1/20 0.38
PDE5A O76074 3/20 0.38
PDE4A P27815 3/20 0.38
PDE4B Q07343 3/20 0.38
PDE4C Q08493 3/20 0.38
PDE4D Q08499 3/20 0.38
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
CYP2C9 P11712 1/20 0.38
KCNH2 Q12809 1/20 0.38
APP P05067 1/20 0.37
MAPT P10636 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714606 0.96 SMO (0.39) SMOMAPK14PARP10METPDE5A
SCHEMBL30714571 0.94 MMP3 (0.40) SMOMAPK14BRD4CREBBPCYP2C9
SCHEMBL30714567 0.93 SMO (0.41) SMOMAPK14BRD4CREBBPCYP2C9
SCHEMBL26868543 0.91 SMO (0.38) SMOMAPK14PARP10METPDE5A
SCHEMBL26868745 0.91 SMO (0.39) SMOMAPK14BRD4CREBBPCYP2C9
SCHEMBL30714748 0.88 HTR3A (0.43) APP
SCHEMBL31539868 0.88 SMO (0.38) SMOMAPK14PARP10METBRD4
SCHEMBL26868971 0.87 SMO (0.40) SMOMAPK14PARP10METBRD4
SCHEMBL26869173 0.86 BRD4 (0.38) SMOMAPK14METPDE5APDE4A
SCHEMBL30714628 0.85 PARP15 (0.40) PARP10METKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 SMO 3806/4885MAPK14 2027/4885PARP10 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.